ArticleDer Internist2018
[Follow-up care for gastrointestinal tumors].
Article in Der Internist, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The follow-up care of patients with gastrointestinal cancer is poorly defined. Prospective trials showing that regular follow-up care is advantageous are largely lacking. Follow-up is primarily based on symptom evaluation, as well as on an assessment of nutritional status and the need for psycho-oncological care. Whereas the evidence for regular endoscopic follow-up is well defined in early cancers, the role of follow-up care in advanced cancers is less well defined. This deficit is mainly due to the lack of therapeutic consequences in the case of recurrence. In such cases, cure is only rarely possible, and most studies have failed to demonstrate a survival benefit following standardized follow-up care of these patients. However, in view of the evolving treatment options in recurrent disease and the success of recurrent colorectal cancer treatment, it seems reasonable to define the current status of follow-up care for patients with gastrointestinal cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.